Korro Bio Inc (KRRO) USD0.001

Sell:$37.10Buy:$42.00$0.59 (1.57%)

Prices delayed by at least 15 minutes
Sell:$37.10
Buy:$42.00
Change:$0.59 (1.57%)
Deal now
Prices delayed by at least 15 minutes
Sell:$37.10
Buy:$42.00
Change:$0.59 (1.57%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Key people

Ram Aiyar
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
Vineet Agarwal
Chief Financial Officer
Todd Chappell
Chief Operating Officer
Jeffrey Cerio
Senior Vice President, General Counsel, Corporate Secretary
Stephanie Engels
Senior Vice President - People and Culture
Venkat Krishnamurthy
Senior Vice President - Platform
Gaozhong Zhu
Senior Vice President of Chemistry, Manufacturing and Controls
Oliver Dolan
Principal Accounting Officer
Loic Vincent
Chief Scientific Officer
Kemi Olugemo
Chief Medical Officer
Nessan Bermingham
Independent Chairman of the Board
Ali Behbahani
Independent Director
Jean-Francois Formela
Independent Director
Katharine Knobil
Independent Director
Rachel Meyers
Independent Director
Click to see more

Key facts

  • Shares in issue
    9.39m
  • EPIC
    KRRO
  • ISIN
    US5009461089
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $389.16m
  • Employees
    92
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.